Puma Biotechnology, Inc. (PBYI)

US — Healthcare Sector
Peers: ELDN  ABEO  VYGR  AVIR  ARCT  ALLO  HUMA  TRDA  SGMT 

Automate Your Wheel Strategy on PBYI

With Tiblio's Option Bot, you can configure your own wheel strategy including PBYI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript
PBYI
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – President and Chief Executive Officer Jeff Ludwig – Chief Commercial Officer Maximo Nougues – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright Marc Frahm – TD Cowen Operator Good afternoon.

Read More
image for news Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript

About Puma Biotechnology, Inc. (PBYI)

  • IPO Date 2012-04-24
  • Website https://www.pumabiotechnology.com
  • Industry Biotechnology
  • CEO Alan H. Auerbach
  • Employees 172
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.